Skip to main content
Erschienen in: Clinical and Translational Oncology 8/2015

01.08.2015 | Research Article

Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?

verfasst von: S. Mohapatra, A. Saxena, G. Gandhi, B. C. Koner, T. Singh, P. C. Ray

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

Vitamin D deficiency is reported to be involved in pathogenesis of ovarian cancer. But the mechanism is yet to be explored. An imbalance between Th1 and Th2 activity play a crucial role in pathogenesis of many cancers. The purpose of the study is to find out the Th1/Th2 status by estimating TNF-α (Th1 marker) and IL-4 (Th2 marker) in ovarian cancer cases and controls and to correlate these with serum vitamin D levels.

Materials and methods

A case–control study with 50 ovarian cancer cases and 50 healthy controls was conducted. The cytokines TNF-α and IL-4 were estimated by ELISA. Serum vitamin D was measured by electro-chemiluminescence immunoassay method.

Results

Median TNF-α levels (12.2 vs 6.2 pg/ml; p value <0.001) were significantly higher in ovarian cancer patients and mean IL-4 levels (2.22 ± 0.51 vs 2.99 ± 0.68 pg/ml; p value <0.05) were significantly lower as compared to those of controls. Levels of TNF-α and IL-4 did not vary significantly with clinical staging, and histological grading. Vitamin D levels were negatively correlated with TNF-α and positively correlated with IL-4.

Conclusions

Low vitamin D levels promotes Th1 activity increasing TNF-α levels and inhibits Th2 activity decreasing IL-4 levels in ovarian cancer. These low levels of vitamin D may induce pro-inflammatory micro ambience which might contribute to pathogenesis of ovarian cancer.
Literatur
2.
Zurück zum Zitat Shan W, Liu J. Inflammation -A hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009;8(19):3107–11.PubMedCrossRef Shan W, Liu J. Inflammation -A hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009;8(19):3107–11.PubMedCrossRef
3.
Zurück zum Zitat Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7–17.PubMedCrossRef Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7–17.PubMedCrossRef
4.
Zurück zum Zitat Borm PJ, Driscoll K. Particles, inflammation and respiratory tract carcinogenesis. Toxicol Lett. 1996;88:109–13.PubMed Borm PJ, Driscoll K. Particles, inflammation and respiratory tract carcinogenesis. Toxicol Lett. 1996;88:109–13.PubMed
5.
Zurück zum Zitat Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol. 1999;21(3):339–59.PubMedCrossRef Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol. 1999;21(3):339–59.PubMedCrossRef
6.
Zurück zum Zitat Aoki Y, Tsuneki I, Sasaki M, Watanabe M, Sato T, Aida H, et al. Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. Gynecol Obstet Invest. 2000;50:207–11.PubMedCrossRef Aoki Y, Tsuneki I, Sasaki M, Watanabe M, Sato T, Aida H, et al. Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. Gynecol Obstet Invest. 2000;50:207–11.PubMedCrossRef
7.
Zurück zum Zitat Skinner ML, Schlosser RJ, Lathers D, Neal JG, Woodworth BA, Hall J, et al. Innate and adaptive mediators in cystic fibrosis and allergic fungal rhinosinusitis. Am J Rhinol. 2007;21(5):538–41.PubMedCrossRef Skinner ML, Schlosser RJ, Lathers D, Neal JG, Woodworth BA, Hall J, et al. Innate and adaptive mediators in cystic fibrosis and allergic fungal rhinosinusitis. Am J Rhinol. 2007;21(5):538–41.PubMedCrossRef
8.
Zurück zum Zitat Seder RA, Paul WE, Davis MM. De St Groth BF. The presence of interleukin-4 during in vitro priming determines the lymphokine producing potential of CD4+T cells from T cell receptor transgenic mice. J Exp Med. 1992;179:1091–8.CrossRef Seder RA, Paul WE, Davis MM. De St Groth BF. The presence of interleukin-4 during in vitro priming determines the lymphokine producing potential of CD4+T cells from T cell receptor transgenic mice. J Exp Med. 1992;179:1091–8.CrossRef
9.
Zurück zum Zitat Mohapatra S, Saxena A, Gandhi G, Koner BC, Ray PC. Vitamin D and VDR gene polymorphism (FokI) in epithelial ovarian cancer in Indian population. J Ovarian Res. 2013;6(1):37.PubMedCentralPubMedCrossRef Mohapatra S, Saxena A, Gandhi G, Koner BC, Ray PC. Vitamin D and VDR gene polymorphism (FokI) in epithelial ovarian cancer in Indian population. J Ovarian Res. 2013;6(1):37.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Mohr SB, Gorham ED, Grant WB, Garland FC. Role of Ultraviolet B Irradiance and vitamin D in Prevention of Ovarian Cancer. Am J Prev Med. 2006;31(6):512–4.PubMedCrossRef Mohr SB, Gorham ED, Grant WB, Garland FC. Role of Ultraviolet B Irradiance and vitamin D in Prevention of Ovarian Cancer. Am J Prev Med. 2006;31(6):512–4.PubMedCrossRef
11.
Zurück zum Zitat Jenab M, Bueno-De-Mesquita HB, Ferrari P, Van Duijnhoven FJ, Norat T, Pischon T, et al. Diagnostic Circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case–control study. BMJ. 2010;340:B5500.PubMedCentralPubMedCrossRef Jenab M, Bueno-De-Mesquita HB, Ferrari P, Van Duijnhoven FJ, Norat T, Pischon T, et al. Diagnostic Circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case–control study. BMJ. 2010;340:B5500.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451–9.PubMedCrossRef Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451–9.PubMedCrossRef
14.
Zurück zum Zitat Sperati F, Vici P, Maugeri-Saccà M, Stranges S, Santesso N, Mariani L, et al. Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(7):e69269.PubMedCentralPubMedCrossRef Sperati F, Vici P, Maugeri-Saccà M, Stranges S, Santesso N, Mariani L, et al. Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(7):e69269.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D (3) receptor in the immune system. Arch Biochem Biophys. 2000;374:334–8.PubMedCrossRef Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D (3) receptor in the immune system. Arch Biochem Biophys. 2000;374:334–8.PubMedCrossRef
16.
Zurück zum Zitat Reichel H, Koeffler HP, Bishop JE, Norman AW. 25-Hydroxyvitamin d3 metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endocrinol Metab. 1987;64(1):1–9.PubMedCrossRef Reichel H, Koeffler HP, Bishop JE, Norman AW. 25-Hydroxyvitamin d3 metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endocrinol Metab. 1987;64(1):1–9.PubMedCrossRef
17.
Zurück zum Zitat Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O’Garra A. 1α,25-Dihydroxyvitamin d3 has a direct effect on naive CD4+T cells to enhance the development of Th2 cells. J Immunol. 2001;167:974–80.CrossRef Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O’Garra A. 1α,25-Dihydroxyvitamin d3 has a direct effect on naive CD4+T cells to enhance the development of Th2 cells. J Immunol. 2001;167:974–80.CrossRef
18.
Zurück zum Zitat Szlosarek PW, GrimshawMJ Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Expression and regulation of tumor necrosis factor A in normal and malignant ovarian epithelium. Mol Cancer Ther. 2006;5(2):382–90.PubMedCrossRef Szlosarek PW, GrimshawMJ Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Expression and regulation of tumor necrosis factor A in normal and malignant ovarian epithelium. Mol Cancer Ther. 2006;5(2):382–90.PubMedCrossRef
19.
Zurück zum Zitat Madhusudan S, Muthuramalingam SR, Braybrooke JP. Study of etanercept, a tumor necrosis factor-α inhibitor, in recurrent ovarian cancer. J Clin Oncol. 2005;23:5950–9.PubMedCrossRef Madhusudan S, Muthuramalingam SR, Braybrooke JP. Study of etanercept, a tumor necrosis factor-α inhibitor, in recurrent ovarian cancer. J Clin Oncol. 2005;23:5950–9.PubMedCrossRef
20.
Zurück zum Zitat Topp MS, Papadimitriou CA, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res. 1995;55(10):2173–6.PubMed Topp MS, Papadimitriou CA, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res. 1995;55(10):2173–6.PubMed
21.
Zurück zum Zitat Goldstein R, Hanley C, Morris J, Cahill D, Chandra A, Harper P, et al. Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. Cancers. 2011;3:4281–93.PubMedCentralPubMedCrossRef Goldstein R, Hanley C, Morris J, Cahill D, Chandra A, Harper P, et al. Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. Cancers. 2011;3:4281–93.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Chang TL, Peng X, Fu XY. Interleukin-4 mediates cell growth inhibition through activation of Stat1. J Biol Chem. 2000;275(14):10212–7.PubMedCrossRef Chang TL, Peng X, Fu XY. Interleukin-4 mediates cell growth inhibition through activation of Stat1. J Biol Chem. 2000;275(14):10212–7.PubMedCrossRef
23.
Zurück zum Zitat Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41.PubMedCrossRef Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41.PubMedCrossRef
24.
Zurück zum Zitat Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):799–810.PubMedCentralPubMedCrossRef Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):799–810.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha, 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35(1):217–24.PubMedCrossRef Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha, 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35(1):217–24.PubMedCrossRef
26.
Zurück zum Zitat Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80:1717S–20S.PubMed Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80:1717S–20S.PubMed
27.
Zurück zum Zitat Jones EA, Pringle JH, Angel CA, Rees RC. Th1/Th2 cytokine expression and its relationship with tumour growth in B cel non-Hodgkin’s lymphoma (NHL). Leuk Lymphoma. 2002;43:1313–21.PubMedCrossRef Jones EA, Pringle JH, Angel CA, Rees RC. Th1/Th2 cytokine expression and its relationship with tumour growth in B cel non-Hodgkin’s lymphoma (NHL). Leuk Lymphoma. 2002;43:1313–21.PubMedCrossRef
Metadaten
Titel
Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?
verfasst von
S. Mohapatra
A. Saxena
G. Gandhi
B. C. Koner
T. Singh
P. C. Ray
Publikationsdatum
01.08.2015
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 8/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1281-3

Weitere Artikel der Ausgabe 8/2015

Clinical and Translational Oncology 8/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.